// App-Quantinova.ai

1629 : Pharmacokinetics (PK), Safety and Overall Response Rate (ORR) Achieved with Subcutaneous (SC) Administration of Rituximab in Combination with Chemotherapy Were Comparable to Those Achieved with Intravenous (IV) Administration in Patients (pts) with Follicular Lymphoma (FL) in the First-Line Setting: Stage 1 Results of the Phase III SABRINA Study (BO22334)

Researchers

Presenter

  • Francesco Merli

Principal Investigators

  • Biljana Mihaljevik

  • Noppadol Siritanaratkul

  • Philippe Solal-Celigny

  • Axel Boehnke

  • Claude Berge

  • Christine McIntyre

  • Martin Barrett

  • David MacDonald

Medical Centers

  • Centre Jean Bernard, Le Mans, France

  • Queen Elizabeth II Health Sciences Centre, Halifax, NS, Canada

  • Division of Hematology, Department of Medicine, Siriraj Hospital, Bangkok, Thailand

  • School of Medicine, Clinic of Hematology, Clinical Centre Serbia, Belgrade, Serbia

  • University of Southampton Faculty of Medicine, Southampton, United Kingdom

Locations

  • Canada

  • Serbia

  • Italy

  • United Kingdom

  • France

  • Thailand

Companies

  • F. Hoffmann-La Roche

  • Feng Chi Biotech Cor

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Follicular lymphoma

  • Neutropenia

  • Lymphomas

Biomarkers

  • N/A

Drug/Treatment

  • Rituximab

Outcome

  • N/A

Study Design

  • open label

  • randomized

Phase

  • NA

Study Id's

  • NCT01200758

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved